Lytix calls in cash

Norwegian company Lytix Biopharma closes a USD 1.4 million funding round to finance new antimicrobial and oncology lead compounds.

Patent inte alltid rätt väg

Varje år skickar svenska universitetsforskare in hundratals patentansökningar, varav en stor del inom life science. Men det är långt ifrån alla upptäckter som t...

A crash course in IP strategy

"Publish, publish, publish!" Sound familiar? So to meet the researcher's wishes, do you scribble a patent application with lipstick on a napkin and send it in? ...

Säkerhetsbrister på barnsjukhus

Knäckte lösenorden till skyddade dokument från prövningar

Symphogen buys tumor blocking technology

The seller is a pioneer in developing ligand traps to treat cancer and other diseases. "An excellent fit with our scientific and strategic focus," said Kirsten ...

Släpper aptitretande rapport

Stockholm Business Region släpper rapport om onkologi för att locka investerare till Stockholm-Uppsalaregionen. – Rapporten ska vara en aptitretare, förklarar Ylva Hultman.

Schizophrenia and bipolar disorder are relatives

Schizophrenia and bipolar disorder have the same genetic causes, according to a study from Karolinska Institutet.

Planerar det regulatoriska arbetet

Anna Törner från SDS ska stötta Lidds med den regulatoriska planen för bolagets läkemedelskandidat mot prostatacancer, där en fas IIb-studie är på gång.

Academy for a new turn at work

Are you qualified within life science, but unemployed? Here is your chance for a new career, in high demand.

Nytt namn i Symphogens ledning

Adriann Sax har utsetts till affärschef på det danska företaget.

Less scars with new product

A new Swedish product for post surgical scar formation enters clinical development.

Time to save for survival

The future is bright for the biotech industry. However, the companies need to cut costs immediately if they want to survive the rough economic times.

Norwegian cancer therapy leaves phase II

New clinical results from Algeta highlights the potential of Alpharadin to treat bone metastases in major cancer indications.

Orexo opens doors eastwards

The drug delivery company has signed a deal for selling a cancer pain treatment in China. "An ideal partner for us" says Torbjörn Bjerke, CEO of Orexo.

Meda gets access to Asia

The biotech giant Meda has recently acquires world-wide rights to the cancer breakthrough pain drug Onsolis.

Seminar program Biotech Forum

Here is the entire seminar program at Biotech Forum September 28-29th

Aprea sparkar igång studie

Första patienten doserad i fas Ib/II-studien med cancerbehandlingen APR-246.

Positive combined cancer therapy

Topotarget announces positive data with new treatment against colorectal cancer.

New Nordic nutrition collaboration

Scandinavian Clinical Nutrition has recently signed a unique Nordic distribution agreement.

Stöd till kvinnliga forskare

17 kvinnliga forskare får halva lönen betald för att jobba i en ledande forskningsmiljö i Vinnova-programmet Vinnmer.

Recipharm launches into biologics manufacturing

Recently a Swedish biomanufacturing facility transfers from Astrazeneca to Recipharm Biologics.

Sales Representative, Applied Biosystems

Raysearch tappar chef

Finanschefen lämnar medtechbolaget i april.

Woman deficit in Swedish research

The IP firm Awapatent will soon launch its Innovation Barometer 2009. This year Awapatent reveals that the statistics is even worse, compared to last year.